What is a primary benefit of inhaled corticosteroids (ICS) for asthmatics?

Inhaled corticosteroids (ICS) are a cornerstone of asthma management, particularly for their ability to control inflammation in the long term. Asthma is characterized by chronic airway inflammation, and ICS work by reducing this inflammation, which helps to prevent asthma symptoms and exacerbations over time. By decreasing the amount of inflammation in the airways, ICS improve overall lung function and help patients achieve better asthma control, leading to fewer flare-ups and a lower risk of serious complications.

Although they are not designed for immediate relief of symptoms, which is primarily the function of short-acting beta-agonists (rescue inhalers), ICS are essential for long-term preventative treatment. Additionally, while they can help reduce the reliance on rescue inhalers, this is a secondary effect of their primary role in inflammation management. ICS do not directly boost the immune system; rather, they modulate the immune response to prevent excessive inflammation that leads to asthma symptoms.